Overview
Corporate Profile
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>
Stock Chart
Stock Quote
| (Common Stock) | |
| Exchange | (US Dollar) |
| Price | |
| Change (%) | |
| Intraday High | |
| Intraday Low | |
| Volume | |
|
|
|
Copyright Nasdaq. Minimum 15 minutes delayed.
RECENT NEWS
More >>| Date | Title | ||||
|---|---|---|---|---|---|
|
04/16/18
|
Summary ToggleClovis Oncology Announces Pricing of Public Offerings of Convertible Senior Notes and Common Stock |
BOULDER, Colo. --(BUSINESS WIRE)--Apr. 16, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the upsizing and pricing of an underwritten public offering of $300 million aggregate principal amount of its 1.25% convertible senior notes due 2025 at a price to the public of 100% of the |
 |
||
|
04/16/18
|
Summary ToggleClovis Oncology Announces Proposed Offerings of Convertible Senior Notes and Common Stock |
BOULDER, Colo. --(BUSINESS WIRE)--Apr. 16, 2018-- Clovis Oncology , Inc. (NASDAQ:CLVS) announced today that it has commenced two separate underwritten public offerings of convertible senior notes and common stock. Clovis intends to offer, subject to market and other conditions, $200 million |
|
||
|
04/06/18
|
Summary ToggleRubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer |
Rubraca is now indicated as maintenance treatment for women with recurrent ovarian cancer who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA mutation status – no biomarker testing required Rubraca received regular approval in this broader and earlier-line |
|